Literature DB >> 4573354

The complement system in bullous pemphigoid. I. Complement and component levels in sera and blister fluids.

R E Jordon, N K Day, W M Sams, R A Good.   

Abstract

Compared with other serum and blister fluid proteins, total hemolytic complement was reduced in the blister fluid of six serologically positive bullous pemphigold patients while four serologically negative cases had blister fluid complement levels closely approaching the serum levels. Except for pemphigus vulgaris blisters. blister fluids from most patients with other bullous diseases and experimentally induced blisters had blister fluid complement levels more closely approaching the serum levels. With the exception of the two terminal components. C8 and C9, individual components of the complement sequence were also reduced in the blister fluids of the six bullous pemphigold patients with circulating basement membrane zone antibodies. On the other hand, transferrin and IgG levels of these same six serologically positive blister fluids closely approached the corresponding serum levels. Conversion of C3 proactivator was also demonstrable in the serologically positive bullous pemphigoid blister fluids, but not in the corresponding sera. Our studies, therefore, are suggestive of local activation of the complement sequence, by both the classical and alternate pathways, in blisters of serologically positive bullous pemphigold patients.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4573354      PMCID: PMC302377          DOI: 10.1172/JCI107288

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

1.  Basement zone antibodies in bullous pemphigoid.

Authors:  R E Jordon; E H Beutner; E Witebsky; G Blumental; W L Hale; W F Lever
Journal:  JAMA       Date:  1967-05-29       Impact factor: 56.272

2.  Immune hemolysis: a simplified method for the preparation of EAC'4 with guinea pig or with human complement.

Authors:  T Borsos; H J Rapp
Journal:  J Immunol       Date:  1967-08       Impact factor: 5.422

3.  Studies in bullous diseases. Immunofluorescent serologic tests.

Authors:  S M Peck; K E Osserman; L B Weiner; A Lefkovits; R S Osserman
Journal:  N Engl J Med       Date:  1968-10-31       Impact factor: 91.245

4.  The presence of complement "bound" in vivo in the skin of patients with pemphigoid.

Authors:  T P Chorzelski; R H Cormane
Journal:  Dermatologica       Date:  1968

5.  Ontogenetic development of the complement system.

Authors:  N K Day; R J Pickering; H Gewurz; R A Good
Journal:  Immunology       Date:  1969-03       Impact factor: 7.397

6.  Autoantibodies in pemphigoid.

Authors:  T Chorzelski; S Jablońska; M Blaszczyk; M Jarzabek
Journal:  Dermatologica       Date:  1968

7.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

8.  Dermo-epidermal separation with suction. Electron microscopic and histochemical study of initial events of blistering on human skin.

Authors:  U Kiistala; K K Mustakallio
Journal:  J Invest Dermatol       Date:  1967-05       Impact factor: 8.551

9.  Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum.

Authors:  R A Nelson; J Jensen; I Gigli; N Tamura
Journal:  Immunochemistry       Date:  1966-03

10.  Complement activity and inflammatory neutrophil exudation in man. Studies in patients with glomerulonephritis, essential hypocomplementemia and agammaglobulinemia.

Authors:  H Gewurz; A R Page; R J Pickering; R A Good
Journal:  Int Arch Allergy Appl Immunol       Date:  1967
View more
  22 in total

1.  Immunologic phenomena in herpes gestationis.

Authors:  S Jablonska; T P Chorzelski; E H Beutner; E Maciejowska; G Rzesa
Journal:  Arch Dermatol Forsch       Date:  1975-07-18

2.  Production of human monoclonal anti-basement membrane zone (BMZ) antibodies from a patient with bullous pemphigoid (BP) by Epstein-Barr virus transformation. Analyses of the heterogeneity of anti-BMZ antibodies in BP sera using them.

Authors:  T Sugi; T Hashimoto; T Hibi; T Nishikawa
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

3.  Editorial: Complement activation and disease.

Authors: 
Journal:  Br Med J       Date:  1976-02-21

4.  C1q binding substances in pemphigus and bullous pemphigoid. Detection with a [131I] C1q binding assay.

Authors:  G Tappeiner; K G Heine; J C Kahl; R E Jordon
Journal:  Clin Exp Immunol       Date:  1977-04       Impact factor: 4.330

5.  Immunopathology of bullous pemphigoid. Basement membrane deposition of IgE, alternate pathway components and fibrin.

Authors:  T T Provost; T B Tomasi
Journal:  Clin Exp Immunol       Date:  1974-10       Impact factor: 4.330

6.  Complement activation in pemphigus vulgaris blister fluid.

Authors:  R E Jordan; N K Day; J R Luckasen; R A Good
Journal:  Clin Exp Immunol       Date:  1973-09       Impact factor: 4.330

Review 7.  Circulating immune complexes in dermatologic disease.

Authors:  T J Lawley; R P Hall
Journal:  Springer Semin Immunopathol       Date:  1981

8.  The role of complement in experimental bullous pemphigoid.

Authors:  Z Liu; G J Giudice; S J Swartz; J A Fairley; G O Till; J L Troy; L A Diaz
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

9.  Complement in pemphigus vulgaris and other bullous dermatoses.

Authors:  E Sbano; A Auteri; M Fimiani; L Volpi
Journal:  Arch Dermatol Res       Date:  1975-12-10       Impact factor: 3.017

Review 10.  The pathophysiology of bullous pemphigoid.

Authors:  Michael Kasperkiewicz; Detlef Zillikens
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.